Cefepime IM Dosage for UTI
For mild to moderate uncomplicated or complicated UTIs, administer cefepime 0.5-1 g intramuscularly every 12 hours for 7-10 days 1.
Key Dosing Parameters
The FDA-approved intramuscular route for cefepime is specifically indicated only for mild to moderate UTIs caused by E. coli 1. This is a critical limitation to understand.
Standard IM Dosing Regimen:
- Dose: 0.5-1 g IM
- Frequency: Every 12 hours
- Duration: 7-10 days
- Indication: Mild to moderate uncomplicated or complicated UTI 1
Important Clinical Caveats
When IM Route is NOT Appropriate:
You must switch to intravenous administration in these scenarios:
- Severe UTIs: Require 2 g IV every 12 hours for 10 days 1
- Pyelonephritis: Guidelines recommend 1-2 g IV twice daily 2
- Pseudomonas aeruginosa infection: Requires 2 g IV every 8 hours 1
- Pathogens other than E. coli: IM route only FDA-approved for E. coli 1
Renal Impairment Adjustment:
The standard dosing above applies only if creatinine clearance >60 mL/min 1. For CrCL ≤60 mL/min, dose adjustments are mandatory as cefepime is 85% renally excreted 1. Elderly patients frequently require adjustment 1.
Clinical Context from Guidelines
Current guidelines position cefepime within the broader treatment framework for UTIs:
- Uncomplicated cystitis: Nitrofurantoin remains first-line to spare broader-spectrum agents 3
- Pyelonephritis requiring IV therapy: Ceftriaxone is the recommended empirical choice in the absence of multidrug resistance risk factors 3
- Complicated UTIs: Extended-spectrum cephalosporins like cefepime are appropriate when parenteral therapy is needed 2
The 2024 EAU guidelines list cefepime at 1-2 g twice daily IV for pyelonephritis, noting the lower dose was studied but higher dose is recommended 2. Beta-lactams for pyelonephritis should be given for 7 days 3.
Practical Application
Use the 1 g IM dose rather than 0.5 g for most adult UTI cases to ensure adequate tissue penetration, given that studies supporting efficacy used comparable exposures 4. Research demonstrates 89% clinical response rates with cefepime 500 mg every 12 hours for complicated UTIs 4, but the higher dose provides additional margin.
The IM route offers 82-100% bioavailability with peak levels at 1-1.6 hours 5, making it suitable for outpatient or step-down therapy in appropriate mild-moderate cases.